Queen's University

Summary

Queen's University is a medical facility located in KINGSTON, Ontario. This center is recognized for care of Depression, Major Depressive Disorder, Motor Skills, Schizophrenia, Osteoarthritis and other specialties. Queen's University is involved with conducting 94 clinical trials across 180 conditions. There are 7 research doctors associated with this hospital, such as Roumen Milev, MD, Davide Bardana, MD, Najat Khalifa, MD, FRCPC, and Karen E Yeates, MD.

Top PIs

Clinical Trials running at Queen's University

Attention Deficit Hyperactivity Disorder (ADHD)

Tourette Syndrome

Depression

Autism Spectrum Disorder

Insomnia

Traumatic Brain Injury

Chronic Kidney Disease

ICU Delirium

Critical Illness

Prostate Cancer

tDCS + Cognitive Training

for Improved Decision Making

This study aims to (i) assess the effects of combined tDCS and cognitive training on decision-making on a trained task (Iowa Gambling Task; IGT); and (ii) test generalization to a closely related cognitive domain, namely motor impulsivity. It is hypothesized that combined anodal tDCS and cognitive training will result in more advantageous decisions and better impulse control than combined sham tDCS and cognitive training.

Recruiting

0 awards

N/A

Sertraline

for Anxiety in Neurodevelopmental Disorders

There are currently no approved medications for the treatment of anxiety in children and youth with neurodevelopmental disorders (NDDs), both common and rare. Sertraline, a selective serotonin reuptake inhibitor, has extensive evidence to support its use in children's and youth with anxiety but not within NDDs. More research is needed to confirm whether or not sertraline could help improve anxiety in children and youth with common and rare neurodevelopmental conditions. This is a pilot study, in which we plan to estimate the effect size of reduction in anxiety of sertraline vs. placebo. across rare and common neurodevelopmental disorders, and determine the best measure(s) to be used as a primary transdiagnostic outcome measure of anxiety, as well as diagnosis specific measures in future, larger-scale clinical trials of anxiety in NDDs.

Recruiting

0 awards

Phase 2

10 criteria